Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nabiximols - GW Pharmaceuticals

Next Previous
Drug Profile

Nabiximols - GW Pharmaceuticals

Alternative Names: Cannabidiol/tetrahydrocannabinol; CBD/THC; CBD:THC; Delta-9-tetrahydrocannabinol/cannabidiol; Delta-9-THC/cannabidiol; Dronabinol/cannabidiol; GW 1000; GW-1000-02; Medicinal cannabis - GW Pharmaceuticals; Nabidiolex®/Tetranabinex®; Sativex; Tetrahydrocannabinol/cannabidiol; THC/CBD; THC:CBD

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Almirall S.A.; GW Pharmaceuticals; Novartis; Otsuka Pharmaceutical
  • Class Analgesics; Anti-ischaemics; Antidementias; Antiemetics; Antiparkinsonians; Antipsychotics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Antioxidants; Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Muscle spasticity; Neuropathic pain
  • Phase I/II Glioblastoma
  • No development reported Bladder dysfunction; Stomatitis

Most Recent Events

  • 11 Nov 2019 Nabiximols licensed to Al-Mojil in Kuwait
  • 11 Nov 2019 Nabiximols licensed to IDS Medical in United Arab Emirates
  • 11 Nov 2019 The National Institute for Health and Care Excellence (NICE) recommends namibixol for treatment of Muscle spasticity due to Multiple sclerosis in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top